Ovid Therapeutics (OVID) Net Income (2016 - 2026)

Ovid Therapeutics' Net Income history runs 11 years deep, the most recent figure standing at -$17.0 million for Q1 2026.

• Quarterly Net Income fell 65.98% year-over-year to -$17.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.2 million (up 3.23% YoY) and the FY2025 annual result came in at -$17.4 million, up 34.12% from the prior year.
• Net Income was -$17.0 million for Q1 2026 at Ovid Therapeutics, down from $9.7 million in the prior quarter.
• Across five years, Net Income topped out at $9.7 million in Q4 2025 and bottomed at -$17.0 million in Q1 2026.
• A 5-year average of -$9.8 million and a median of -$12.0 million in 2022 frame the typical range for Net Income.
• Peak annual rise in Net Income reached 204.43% in 2025, while the deepest fall reached 154.97% in 2025.
• Ovid Therapeutics' Net Income stood at -$11.5 million in 2022, then tumbled by 33.18% to -$15.3 million in 2023, then surged by 39.61% to -$9.3 million in 2024, then surged by 204.43% to $9.7 million in 2025, then plunged by 275.8% to -$17.0 million in 2026.
• Business Quant data shows OVID's Net Income at -$17.0 million in Q1 2026, $9.7 million in Q4 2025, and -$12.2 million in Q3 2025.